A Phase 3 interventional study of RSVPreF3 OA investigational vaccine and FLU-QIV in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 14 sites in 3 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-03.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 9th largest by enrollment, is one of 4 that started in 2021, is one of 15 in phase 3, and was the 2nd registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 4 started in 2021.
This study's enrollment of 976 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 976 across the 17 interventional studies. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline: 1 open now, 5 under way, 3 of them phase 3. Of 33 finished, 30 (91%) have results posted.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 16th largest by enrollment, is one of 6 that started in 2021, is one of 21 in phase 3, and was the 18th registered.
GlaxoSmithKline’s Respiratory Syncytial Virus Infections studies by the year they started, since 2013.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, from their registry updates:
Among GlaxoSmithKline’s 40 in Respiratory Syncytial Virus Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the seasonal quadrivalent influenza vaccine (FLU-QIV) in adults aged 60 years and above compared to separate administration of the vaccines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medical conditions
Prior/Concomitant therapy
Note: In case an emergency mass vaccination for an unforeseen public health threat is recommended and/or organized by the public health authorities, outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly.
Prior/Concurrent clinical study experience
Other exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 1 dose of RSV_PreF3 Older Adult (OA) investigational vaccine and 1 dose of FLU-QIV at Day 1 and were followed up until the study end.
Biological: RSVPreF3 OA investigational vaccine · Biological: FLU-QIV
Participants received 1 dose of FLU-QIV at Day 1 and 1 dose of RSV_PreF3 OA investigational vaccine at Day 31 and were followed up until the study end.
Biological: RSVPreF3 OA investigational vaccine · Biological: FLU-QIV
RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
FLU-QIV administered intramuscularly in the deltoid region of the dominant (Co-Ad Group) arm or the non-dominant (Control Group) arm.
RSV-A Neutralization Antibody Titers Expressed as Geometric Mean Titers (GMTs)
The serum neutralization assay is a functional assay that measures the ability of serum antibodies to neutralize RSV-A entry and replication in a host cell line. The serum neutralizing antibody titer is expressed in ED60 (Estimated Dilution 60) and corresponds to the inverse of the interpolated serum dilution that yields a 60% reduction of the signal compared to a control without serum.
Time frame: At 1 month after the RSV_PreF3 OA investigational vaccine dose (at Day 31 for the Co-Ad Group and at Day 61 for the Control Group)
Hemagglutinin Inhibition (HI) Antibody Titers for Each of the FLU Vaccine Strains Expressed as Group GMTs
HI antibody titers were assessed for each of the Flu vaccine strains, namely Flu A/Hong Kong/2671/2019 (H3N2), Flu A/Victoria/2570/2019 (H1N1), Flu B/Phuket/3073/2013 (Yamagata) and Flu B/Washington/02/2019 (Victoria). The serum HI antibody titers are expressed in 1/Dilution (DIL) where DIL corresponds to the highest dilution that shows complete HI.
Time frame: 1 month after the FLU vaccine dose (at Day 31)
Secondary: HI Seroconversion Status for Each of the Flu Vaccine Strains Expressed as Seroconversion Rate (SCR)
SCR for HI antibody response was defined as the percentage of vaccinees who have either a HI pre-dose titer \< 1:10 and a post-dose titer \>= 1:40 or a pre-dose titer \>= 1:10 and at least a four-fold increase in post-dose titer. HI antibody titers were assessed for each of the Flu vaccine strains, namely Flu A/Hong Kong/2671/2019 (H3N2), Flu A/Victoria/2570/2019 (H1N1), Flu B/Phuket/3073/2013 (Yamagata) and Flu B/Washington/02/2019 (Victoria).
Time frame: 1 month after the FLU vaccine dose (at Day 31)
RSV-A Neutralization Antibody Titers Expressed as Mean Geometric Increase (MGI)
MGI was defined as the geometric mean of the within participant ratios of the post dose titer over the pre-dose titer.
Time frame: 1 month after the RSV_PreF3 OA investigational vaccine dose (at Day 31 for the Co-Ad Group and at Day 61 for the Control Group)
RSV-B Neutralization Antibody Titers Expressed as Geometric Mean Titers (GMT)
The serum neutralization assay is a functional assay that measures the ability of serum antibodies to neutralize RSV-B entry and replication in a host cell line. The serum neutralizing antibody titer is expressed in ED60 (Estimated Dilution 60) and corresponds to the inverse of the interpolated serum dilution that yields a 60% reduction of the signal compared to a control without serum.
Time frame: 1 month after the RSV_PreF3 OA investigational vaccine dose (at Day 31 for the Co-Ad Group and at Day 61 for the Control Group)
RSV-B Neutralization Antibody Titers Expressed as MGI
MGI was defined as the geometric mean of the within participant ratios of the post-dose titer over the pre-dose titer.
Time frame: 1 month after the RSV_PreF3 OA investigational vaccine dose (at Day 31 for the Co-Ad Group and at Day 61 for the Control Group)
HI Antibody Titers for Each of the FLU Vaccine Strains Expressed as GMTs
HI antibody titers were assessed for each of the Flu vaccine strains, namely A/Hong Kong/2671/2019 (H3N2), Flu A/Victoria/2570/2019 (H1N1), Flu B/Phuket/3073/2013 (Yamagata) and Flu B/Washington/02/2019 (Victoria). The serum HI antibody titers are expressed in 1/DIL where DIL corresponds to the highest dilution that shows complete HI.
Time frame: At baseline (at Day 1) and 1 month after the FLU vaccine dose (at Day 31)
HI Seroprotection Status for Each of the FLU Vaccine Strains Expressed as Seroprotection Rate (SPR)
SPR for HI antibody response was defined as percentage of vaccinees with a serum HI titer \>= 1:40 that usually is accepted as indicating protection. HI antibody titers were assessed for each of the Flu vaccine strains, namely A/Hong Kong/2671/2019 (H3N2), Flu A/Victoria/2570/2019 (H1N1), Flu B/Phuket/3073/2013 (Yamagata) and Flu B/Washington/02/2019 (Victoria).
Time frame: At baseline (at Day 1) and 1 month after the FLU vaccine dose (at Day 31)
HI Antibody Titers for Each of the FLU Vaccine Strains Expressed as MGI
MGI was defined as the geometric mean of the within participant ratios of the post-dose titer over the pre-dose titer. HI antibody were assessed for each of the FLUvaccine strain, namely A/Hong Kong/2671/2019 (H3N2), Flu A/Victoria/2570/2019 (H1N1), Flu B/Phuket/3073/2013 (Yamagata) and Flu B/Washington/02/2019 (Victoria).
Time frame: 1 month after the FLU vaccine dose (at Day 31)
Percentage of Participants With Solicited Administration Site Events
Solicited administration site adverse events(AEs) assessed were erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade.
Time frame: Within 4 days (the day of vaccination and 3 subsequent days) after each vaccination
Percentage of Participants With Solicited Systemic Events
Solicited systemic events assessed were arthralgia, fatigue, fever \[defined as temperature equal to or above (\>=) 38 degrees Celsius (C)/100.4 degrees Fahrenheit (F)\], headache and myalgia. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination.
Time frame: Within 4 days (the day of vaccination and 3 subsequent days) after each vaccination
Percentage of Participants Reporting at Least One Unsolicited Adverse Event
An unsolicited AEs is any AE reported in addition to those solicited during the clinical study and that was not included in a list of solicited events using a Participant Diary. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event. Unsolicited AEs include serious, non-serious AEs and potential immune-mediated diseases (pIMDs). Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: Within 30 days (the day of vaccination and 29 subsequent days) after each vaccination
Percentage of Participants Reporting at Least One Serious Adverse Event (SAE)
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination.
Time frame: From Day 1 up to study end (6 months after last vaccination)
Percentage of Participants Reporting at Least One Potential Immune-mediated Disease (pIMD)
pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Time frame: From Day 1 up to study end (6 months after last vaccination)
| Milestone | Co-Ad Group | Control Group |
|---|---|---|
| Started | 442 | 443 |
| Completed | 429 | 417 |
| Not completed | 13 | 26 |
| Withdrew: Adverse event | 5 | 10 |
| Withdrew: Lost to follow-up | 8 | 7 |
| Withdrew: Consent withdrawal, not due to a (s)ae | 0 | 8 |
| Withdrew: Other | 0 | 1 |
The serum neutralization assay is a functional assay that measures the ability of serum antibodies to neutralize RSV-A entry and replication in a host cell line. The serum neutralizing antibody titer is expressed in ED60 (Estimated Dilution 60) and corresponds to the inverse of the interpolated serum dilution that yields a 60% reduction of the signal compared to a control without serum.
| Titers (ED 60) | Co-Ad Group | Control Group |
|---|---|---|
| RSV-A Neutralization Antibody Titers Expressed as Geometric Mean Titers (GMTs) | 10060.5 (9126 to 11090.7) | 12255 (11160.4 to 13456.9) |
HI antibody titers were assessed for each of the Flu vaccine strains, namely Flu A/Hong Kong/2671/2019 (H3N2), Flu A/Victoria/2570/2019 (H1N1), Flu B/Phuket/3073/2013 (Yamagata) and Flu B/Washington/02/2019 (Victoria). The serum HI antibody titers are expressed in 1/Dilution (DIL) where DIL corresponds to the highest dilution that shows complete HI.
| Titers (1/DIL) | Co-Ad Group | Control Group |
|---|---|---|
| Flu A/Hong Kong/2671/2019 H3N2 | 295.2 (263.6 to 330.6) | 346.8 (306.6 to 392.3) |
| Flu A/Victoria/2570/2019 H1N1 | 267.1 (235.6 to 302.8) | 325.4 (282.5 to 374.9) |
| Flu B/Phuket/3073/2013 Yamagata | 28.9 (26 to 32.1) | 34.8 (31.1 to 39.0) |
| Flu B/Washington/02/2019 Victoria | 41.6 (37.1 to 46.6) | 47.9 (41.9 to 54.8) |
SCR for HI antibody response was defined as the percentage of vaccinees who have either a HI pre-dose titer \< 1:10 and a post-dose titer \>= 1:40 or a pre-dose titer \>= 1:10 and at least a four-fold increase in post-dose titer. HI antibody titers were assessed for each of the Flu vaccine strains, namely Flu A/Hong Kong/2671/2019 (H3N2), Flu A/Victoria/2570/2019 (H1N1), Flu B/Phuket/3073/2013 (Yamagata) and Flu B/Washington/02/2019 (Victoria).
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| Flu A/Hong Kong/2671/2019 H3N2 | 54.3 (49.5 to 59.1) | 56.9 (52.0 to 61.8) |
| Flu A/Victoria/2570/2019 H1N1 | 78.9 (74.7 to 82.7) | 83.5 (79.5 to 86.9) |
| Flu B/Phuket/3073/2013 Yamagata | 28.8 (24.6 to 33.4) | 32.8 (28.3 to 37.6) |
| Flu B/Washington/02/2019 Victoria | 35.6 (31.1 to 40.3) | 36 (31.4 to 40.9) |
MGI was defined as the geometric mean of the within participant ratios of the post dose titer over the pre-dose titer.
| Ratio | Co-Ad Group | Control Group |
|---|---|---|
| RSV-A Neutralization Antibody Titers Expressed as Mean Geometric Increase (MGI) | 9.61 (8.7 to 10.61) | 12.95 (11.75 to 14.28) |
The serum neutralization assay is a functional assay that measures the ability of serum antibodies to neutralize RSV-B entry and replication in a host cell line. The serum neutralizing antibody titer is expressed in ED60 (Estimated Dilution 60) and corresponds to the inverse of the interpolated serum dilution that yields a 60% reduction of the signal compared to a control without serum.
| Titers (ED 60) | Co-Ad Group | Control Group |
|---|---|---|
| RSV-B Neutralization Antibody Titers Expressed as Geometric Mean Titers (GMT) | 10518.6 (9302 to 11894.3) | 14349.7 (12640.6 to 16289.9) |
MGI was defined as the geometric mean of the within participant ratios of the post-dose titer over the pre-dose titer.
| Ratio | Co-Ad Group | Control Group |
|---|---|---|
| RSV-B Neutralization Antibody Titers Expressed as MGI | 7.67 (6.76 to 8.72) | 9.28 (8.06 to 10.69) |
HI antibody titers were assessed for each of the Flu vaccine strains, namely A/Hong Kong/2671/2019 (H3N2), Flu A/Victoria/2570/2019 (H1N1), Flu B/Phuket/3073/2013 (Yamagata) and Flu B/Washington/02/2019 (Victoria). The serum HI antibody titers are expressed in 1/DIL where DIL corresponds to the highest dilution that shows complete HI.
| Titers (1/DIL) | Co-Ad Group | Control Group |
|---|---|---|
| Flu A/Hong Kong/2671/2019 H3N2, Day 1 | 61.4 (53.8 to 69.9) | 63.3 (55.7 to 71.9) |
| Flu A/Hong Kong/2671/2019 H3N2, Day 31 | 295.2 (263.6 to 330.6) | 346.8 (306.6 to 392.3) |
| Flu A/Victoria/2570/2019 H1N1, Day 1 | 20 (18 to 22.3) | 19.9 (17.8 to 22.2) |
| Flu A/Victoria/2570/2019 H1N1, Day 31 | 267.1 (235.6 to 302.8) | 325.4 (282.5 to 374.9) |
| Flu B/Phuket/3073/2013 Yamagata, Day 1 | 10.4 (9.5 to 11.3) | 10.8 (9.9 to 11.7) |
| Flu B/Phuket/3073/2013 Yamagata, Day 31 | 28.9 (26 to 32.1) | 34.8 (31.1 to 39) |
| Flu B/Washington/02/2019 Victoria, Day 1 | 12.2 (11.1 to 13.4) | 13.5 (12.2 to 15.1) |
| Flu B/Washington/02/2019 Victoria, Day 31 | 41.6 (37.1 to 46.6) | 47.9 (41.9 to 54.8) |
SPR for HI antibody response was defined as percentage of vaccinees with a serum HI titer \>= 1:40 that usually is accepted as indicating protection. HI antibody titers were assessed for each of the Flu vaccine strains, namely A/Hong Kong/2671/2019 (H3N2), Flu A/Victoria/2570/2019 (H1N1), Flu B/Phuket/3073/2013 (Yamagata) and Flu B/Washington/02/2019 (Victoria).
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| Flu A/Hong Kong/2671/2019 H3N2, Day 1 | 70.8 (66.3 to 75) | 70.3 (65.7 to 74.5) |
| Flu A/Hong Kong/2671/2019 H3N2, Day 31 | 97.4 (95.4 to 98.7) | 97.1 (95 to 98.5) |
| Flu A/Victoria/2570/2019 H1N1, Day 1 | 35.4 (30.9 to 40.1) | 34.6 (30.1 to 39.2) |
| Flu A/Victoria/2570/2019 H1N1, Day 31 | 94.6 (92 to 96.6) | 93.4 (90.6 to 95.6) |
| Flu B/Phuket/3073/2013 Yamagata, Day 1 | 14.3 (11.1 to 17.9) | 14.9 (11.7 to 18.6) |
| Flu B/Phuket/3073/2013 Yamagata, Day 31 | 47.8 (43 to 52.6) | 54.3 (49.3 to 59.2) |
| Flu B/Washington/02/2019 Victoria, Day 1 | 20 (16.3 to 24.1) | 23.6 (19.7 to 27.8) |
| Flu B/Washington/02/2019 Victoria, Day 31 | 59.3 (54.4 to 64) | 61.3 (56.4 to 66) |
MGI was defined as the geometric mean of the within participant ratios of the post-dose titer over the pre-dose titer. HI antibody were assessed for each of the FLUvaccine strain, namely A/Hong Kong/2671/2019 (H3N2), Flu A/Victoria/2570/2019 (H1N1), Flu B/Phuket/3073/2013 (Yamagata) and Flu B/Washington/02/2019 (Victoria).
| Ratio | Co-Ad Group | Control Group |
|---|---|---|
| Flu A/Hong Kong/2671/2019 H3N2 | 4.81 (4.22 to 5.48) | 5.50 (4.81 to 6.29) |
| Flu A/Victoria/2570/2019 H1N1 | 13.36 (11.58 to 15.42) | 16.25 (14.08 to 18.76) |
| Flu B/Phuket/3073/2013 Yamagata HI | 2.82 (2.55 to 3.12) | 3.22 (2.90 to 3.58) |
| Flu B/Washington/02/2019 Victoria | 3.43 (3.06 to 3.85) | 3.60 (3.18 to 4.08) |
Solicited administration site adverse events(AEs) assessed were erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| Erythema against Flu Dose given at Day 1 | 1.1 (0.4 to 2.6) | 0.5 (0.1 to 1.6) |
| Erythema against RSV Dose given at Day 1 | 4.1 (2.5 to 6.4) | — |
| Erythema against RSV Dose given at Day 31 | — | 2.1 (1 to 4) |
| Pain against Flu Dose given at Day 1 | 28.3 (24.1 to 32.8) | 20.5 (16.9 to 24.6) |
| Pain against RSV Dose given at Day 1 | 47.9 (43.2 to 52.7) | — |
| Pain against RSV Dose give at Day 31 | — | 39.1 (34.4 to 44) |
| Swelling against Flu Dose given at Day 1 | 1.4 (0.5 to 3) | 0.7 (0.1 to 2) |
| Swelling against RSV Dose given at Day 1 | 3.2 (1.8 to 5.3) | — |
| Swelling against RSV Dose given at Day 31 | — | 1 (0.3 to 2.4) |
Solicited systemic events assessed were arthralgia, fatigue, fever \[defined as temperature equal to or above (\>=) 38 degrees Celsius (C)/100.4 degrees Fahrenheit (F)\], headache and myalgia. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| Arthralgia, Dosing at Day 1 | 16.2 (12.9 to 20) | 4.8 (3 to 7.2) |
| Arthralgia, Dosing at Day 31 | — | 11.2 (8.4 to 14.6) |
| Fatigue, Dosing at Day 1 | 22.4 (18.6 to 26.6) | 12.8 (9.8 to 16.3) |
| Fatigue, Dosing at Day 31 | — | 17.9 (14.3 to 21.9) |
| Fever, Dosing at Day 1 | 2.5 (1.3 to 4.4) | 0.7 (0.1 to 2) |
| Fever, Dosing at Day 31 | — | 1 (0.3 to 2.4) |
| Headache, Dosing at Day 1 | 21.7 (17.9 to 25.8) | 12.8 (9.8 to 16.3) |
| Headache, Dosing at Day 31 | — | 16.2 (12.8 to 20.1) |
| Myalgia, Dosing at Day 1 | 22.1 (18.3 to 26.3) | 9.4 (6.8 to 12.5) |
| Myalgia, Dosing at Day 31 | — | 19.6 (15.9 to 23.7) |
An unsolicited AEs is any AE reported in addition to those solicited during the clinical study and that was not included in a list of solicited events using a Participant Diary. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event. Unsolicited AEs include serious, non-serious AEs and potential immune-mediated diseases (pIMDs). Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| Percentage of Participants Reporting at Least One Unsolicited Adverse Event | 18.8 (15.2 to 22.7) | 23.7 (19.8 to 27.9) |
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination.
| Percentage of Participants | Co-Ad Group | Control Group |
|---|---|---|
| Percentage of Participants Reporting at Least One Serious Adverse Event (SAE) | 3.4 (1.9 to 5.5) | 4.5 (2.8 to 6.9) |
pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| Percentage of Participants Reporting at Least One Potential Immune-mediated Disease (pIMD) | 1.1 (0.4 to 2.6) | 0.2 (0 to 1.3) |
Collected over Solicited AEs were collected during the 4-day follow-up period after vaccination. Unsolicited AEs were collected during the 30-day follow-up period after vaccination. SAEs and pIMDs were collected throughout the study period (from Day 1 to Study end (6 months after last vaccination)).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Co-Ad Group | 4/442 (0.9%) | 15/442 (3.4%) | 290/442 (65.6%) |
| Control Group | 8/443 (1.8%) | 20/443 (4.5%) | 276/443 (62.3%) |
| Event | Co-Ad Group | Control Group |
|---|---|---|
| DeathGeneral disorders | 4/442 | 8/443 |
| COVID-19Infections and infestations | 2/442 | 3/443 |
| Suspected COVID-19Infections and infestations | 1/442 | 3/443 |
| Acute disseminated encephalomyelitisNervous system disorders | 2/442 | 0/443 |
| AnaemiaBlood and lymphatic system disorders | 1/442 | 0/443 |
| Cardiac failure congestiveCardiac disorders | 1/442 | 0/443 |
| DiverticulitisInfections and infestations | 1/442 | 0/443 |
| COVID-19 pneumoniaInfections and infestations | 1/442 | 0/443 |
| Urinary tract infectionInfections and infestations | 1/442 | 0/443 |
| Subdural haematomaInjury, poisoning and procedural complications | 1/442 | 0/443 |
| Event | Co-Ad Group | Control Group |
|---|---|---|
| Injection site painGeneral disorders | 236/442 | 192/443 |
| FatigueGeneral disorders | 100/442 | 106/443 |
| HeadacheNervous system disorders | 99/442 | 103/443 |
| MyalgiaMusculoskeletal and connective tissue disorders | 98/442 | 100/443 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 73/442 | 60/443 |
| Injection site erythemaGeneral disorders | 21/442 | 11/443 |
| Injection site swellingGeneral disorders | 16/442 | 8/443 |
| PyrexiaGeneral disorders | 14/442 | 6/443 |
| Upper respiratory tract infectionInfections and infestations | 4/442 | 10/443 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/442 | 3/443 |
| Age, Continuous(Years) | Co-Ad Group | Control Group | Total |
|---|---|---|---|
| Mean | 68.4 ± 6.9 | 68.6 ± 6.9 | 68.5 ± 6.9 |
| Sex: Female, Male(Participants) | Co-Ad Group | Control Group | Total |
|---|---|---|---|
| Female | 228 | 228 | 456 |
| Male | 214 | 215 | 429 |
| Race/Ethnicity, Customized(Participants) | Co-Ad Group | Control Group | Total |
|---|---|---|---|
| Asian | 4 | 5 | 9 |
| Black Or African American | 72 | 70 | 142 |
| Maori | 7 | 5 | 12 |
| Mixed Race | 218 | 227 | 445 |
| Native Hawaiian Or Other Pacific Islander | 2 | 1 | 3 |
| Other, Not Specified | 2 | 0 | 2 |
| White | 137 | 135 | 272 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Apr 2021 to primary completion in Sep 2021, 4 months.
Results were first posted in Oct 2022, 1 year after primary completion.
Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 4 months is below that.
Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arexvy
Respiratory Syncytial Virus Infections →